Neonatal Thrombocytopenia: Diagnosis and Platelet Transfusion Triggers

Neonatal thrombocytopenia, defined as a platelet count below 150 × 10⁹/L in newborns, remains one of the most frequent haematological abnormalities encountered in the perinatal period. The condition affects roughly 1–5% of all neonates and rises to 20–30% in those admitted to special care nurseries or tertiary neonatal intensive care units. Because platelet physiology in the newborn differs substantially from older children and adults, clinicians working in Australian neonatal units must combine careful clinical reasoning with an understanding of gestational age–specific norms.

A growing body of international evidence, including material presented at congresses such as the federation's Tokyo programme, has refined how clinicians think about thresholds for transfusion, the triggers that prompt intervention, and the differential diagnoses that should be considered before a single millilitre of blood product is given. This article summarises the contemporary approach for clinicians practising along the eastern seaboard from Cairns to Melbourne, and in the regional and remote centres where retrieval services bridge the gap between small units and tertiary hospitals.

Defining the Condition and Its Prevalence

Platelet counts in healthy term newborns generally fall within the same range as older children, although the lower limit of normality can dip slightly during the first few days of life. In preterm infants, the expected nadir is more pronounced, particularly between days 5 and 7, when counts may transiently drop into a range that would be considered alarming in an older patient but often reflects normal transitional physiology. Recognising where the line lies between expected and pathological is the foundation of sound decision-making.

Incidence figures vary with the population screened. Data from Australian tertiary centres, including the neonatal services at the Royal Women's Hospital in Melbourne and the Royal Brisbane and Women's Hospital, suggest that approximately one in four infants under 28 weeks' gestation will develop a platelet count below 100 × 10⁹/L at some point during their admission. Most of these episodes are mild, self-limited, and require no intervention. The clinical challenge is to distinguish these benign patterns from the smaller group of infants in whom thrombocytopenia signals a serious underlying disorder.

Causes and Classification

Causes of low platelet counts in newborns are conventionally grouped into early-onset (within the first 72 hours) and late-onset (after 72 hours) categories. Early-onset thrombocytopenia most commonly reflects chronic fetal hypoxia, intrauterine growth restriction, alloimmune destruction, or congenital infection. Chronic fetal hypoxia associated with placental insufficiency and growth restriction is the single most frequent cause in well-resourced settings such as those in metropolitan Sydney, Adelaide, and Perth, where antenatal surveillance is well established.

Late-onset thrombocytopenia is dominated by sepsis, necrotising enterocolitis, and acquired consumptive processes. In preterm infants with central venous access, line-associated thrombosis and catheter-related sepsis together account for a substantial proportion. Alloimmune thrombocytopenia, caused by maternal antibodies directed against fetal platelet antigens (most commonly HPA-1a), can present either early or late depending on the timing of intracranial haemorrhage, and warrants urgent identification because of the risk of severe bleeding into the central nervous system.

Diagnostic Workup and Evaluation

A structured approach to the underlying aetiology begins with a careful review of the pregnancy and birth history. Maternal conditions such as pre-eclampsia, autoimmune disease, and drug exposure should be actively sought, as each carries distinct implications for the neonate. A full blood count with manual differential, alongside a blood film review, provides essential clues: small platelets suggest Wiskott-Aldrich or related syndromes, while large platelets raise the possibility of Bernard-Soulier or congenital amegakaryocytic thrombocytopenia.

Microbiological investigation, including blood cultures and viral PCR panels tailored to congenital infections such as cytomegalovirus, toxoplasmosis, and rubella, is standard. In Australia, where maternal serology is comprehensively documented, results are usually rapidly available. Coagulation studies, fibrinogen, and D-dimer help to identify disseminated intravascular coagulation, while cranial ultrasound is recommended in infants with severe thrombocytopenia, particularly those born before 30 weeks' gestation or with concerning clinical signs. Discharge planning draws on follow-up clinic models developed in major perinatal centres to track haematological recovery and neurodevelopmental progress.

Transfusion Triggers and Thresholds

The decision to transfuse platelets has shifted significantly over the past two decades, away from liberal use and towards more restrictive thresholds informed by large randomised trials. For stable infants with counts between 50 and 100 × 10⁹/L, the balance of current evidence supports withholding transfusion in the absence of bleeding. For unstable infants, particularly those with sepsis, fluctuating ventilation requirements, or recent surgery, thresholds of 50 × 10⁹/L are commonly applied.

Prophylactic transfusion thresholds differ by gestational age and clinical condition. Many Australian units now follow the National Blood Authority patient blood management framework and the recommendations of the Australian and New Zealand Society of Blood Transfusion, which align with international consensus. The trigger for transfusion in preterm infants below 32 weeks without bleeding is typically a count of 25 × 10⁹/L, rising to 50 × 10⁹/L for those who are clinically unstable, and to 100 × 10⁹/L for infants with active bleeding or undergoing invasive procedures. The preferred product remains apheresis-derived, pathogen-reduced platelets suspended in platelet additive solution, supplied by Australian Red Cross Lifeblood from processing centres in Sydney and Melbourne.

Special Populations and Procedural Considerations

Certain neonatal populations warrant a more nuanced approach. Infants with neonatal alloimmune thrombocytopenia often present with severe thrombocytopenia at birth and a high risk of intracranial haemorrhage, requiring immediate transfusion of antigen-negative platelets and consideration of intravenous immunoglobulin. Those with chronic lung disease, pulmonary hypertension, or post-haemorrhagic ventricular dilatation may tolerate lower counts poorly, given the precarious balance between bleeding risk and the consequences of fluid overload from repeated transfusions.

Procedural planning is equally important. For lumbar puncture, central line placement, or surgical procedures such as laparotomy for necrotising enterocolitis, a target of 50–100 × 10⁹/L is generally recommended depending on the procedure and the underlying risk. In regional Australian centres, where specialist haematology advice may not be immediately available, teleconsultation with tertiary teams and retrieval by neonatal emergency transport services helps ensure that infants in Townsville, Hobart, or far north Queensland receive care consistent with metropolitan standards.

Australian Practice and Clinical Pathways

Australian practice benefits from a coordinated regulatory environment that is unusual internationally. The National Blood Authority issues patient blood management guidelines that include dedicated neonatal modules, while Lifeblood provides a single national supplier of platelet products with rigorous quality standards. Pathogen reduction is increasingly available for neonatal units that wish to minimise residual risk from bacterial contamination.

Equitable access remains a consideration. Rural and remote families often face prolonged separation from their infants during tertiary admissions, an issue that has prompted several state governments to fund accommodation and travel subsidies. Embedding neonatal thrombocytopenia management within a wider perinatal quality framework, including the work of the Australasian Neonatal Association and the Perinatal Society of Australia and New Zealand, supports consistent care from Darwin to Canberra. Recent presentations at international meetings, including the INS 2018 poster sessions, continue to shape local protocols through shared evidence.

Engage with the latest perinatal and neonatal research shared through international meetings by exploring the FAOPS 2020 programme archive, where presentations on bleeding disorders and transfusion medicine remain a useful reference for Australian clinicians refining their local protocols and training the next generation of neonatal staff.